Liver Tumors Clinical Trial
Official title:
Liver Resection After Portal Vein Ligation / Embolization and Transection Plane Devascularization With Radio Frequency / Microwave: Pilot Study on Primary and Secondary Liver Tumors
One of the limiting factors in the execution of a liver resection, in particular an extended
liver resection, it's represented by the future remnant liver (FRL) after hepatic surgery.
In cases of normal organ function an FRL of 25% is considered sufficient. In case of
impaired hepatic function or a history of chemotherapy, it is considered safe if at least of
40%.
Many strategies have been developed and proposed to increase the resectability in patients
undergoing major liver resections.
One of these is a new two-stage technique proposed recently by a group of German surgeons.
This approach consists in the ligation of the right portal vein associated with resection of
the liver along the falciform ligament (step 1). Step 2, after a period of 9 days (median -
5-25 days), after a volumetric CT to ensure an adeguate hypertrophy of the left lateral lobe
due to the combination of right portal occlusion and segment 4 devascularization, the
patient undergo a right trisectionectomy. The hypertrophy of the left lateral lobe is shown
to be of 74%, higher than any other techniques of ligation or portal embolizatiol proposed
in the literature.
On the basis of the clinical experiences reported the investigators designed a new protocol
of two-stage hepatic resection for the treatment of primary or secondary tumors of the right
lobe. Step1: laparoscopic radio frequency / microwave ablation of the future transection
plane between segment 4 and left lateral lobe and surgical ligation or embolization of the
right portal vein. The ablation has the purpose to devascularize the segment 4 and has the
same significance of the resection of the liver along the falciform ligament described by
the Regensburg group.
Step2: After a period of time of 9 ± 2 days, following a volumetric CT showing an adequate
liver volume gain (ratio FRL / patient body weight> 0.5), the patient undergo the
second-stage surgery: laparoscopic/ laparotomic right trisectionectomy.
In patients with primary or metastatic liver tumors, the only potentially curative
therapeutic option is represented by hepatic resection. Nowdays extended resections can be
performed with acceptable morbidity and mortality. There is no unanimous definition on the
criteria of resectability and the ability to perform a more or less extensive liver
resection is deferred to the expertise of the center and the surgical team. The
investigators will consider a tumor resectable if the surgical procedure does not damage
vital structures, the normal function of the organ is preserved and and the tumor is
completely removed (R0 resection). One of the limiting factors in the execution of a liver
resection, in particular if it is extended, it's represented by the future remnant liver
(FRL) after hepatic resection. In cases of normal organ function an FRL of 25% is considered
sufficient. In case of impaired hepatic function or a history of chemotherapy, it is
considered safe if at least of 40%.
Many methods have been developed and proposed to increase the resectability in patients
undergoing major liver resections. In case of bilobar tumor, a two-step approach (two-stage
hepatectomy)have been proposed. This procedure implies that one of the two lobes is
initially freed of disease by tumor resection or ablation. After achieving an adequate
compensatory hypertrophy of the lobe freed by the tumor (usually 4-6 weeks),a contralateral
liver resection can be done to treat the remnant tumor.
To increase the FRL another approach is to occlude the portal branches towards one of liver
lobes. This can be done with a surgical ligation (laparotomy or laparoscopy) or
radiologically, using portal embolization. The technique allows to increase from 10% to 46%
of the FRL with the possibility of obtaining a resection R-0 in 70-100% of cases. It is
unclear whether there is any difference between the methods of portal occlusion (ligation vs
embolization). To further increase hypertrophy after portal occlusion in liver tumors
occupying the right liver, some researchers proposed to embolize the portal branches of
segment 4th together with the right portal vein.
The group of Regensburg has introduced a new technique in two stages for tumors of the right
lobe, which combines the methods mentioned above. This two-stage approach consists in the
ligation of the right portal vein associated with resection of the liver along the falciform
ligament (step 1). Step 2, after a period of 9 days (median - 5-25 days), after a volumetric
CT to ensure an adeguate hypertrophy of the left lateral lobe, the patient undergo a right
trisectionectomy. The hypertrophy of the left lateral lobe is shown to be of 74%, higher
than any other techniques of ligation or portal embolizatiol proposed in the literature.
The rationale of this technique is the complete portal devascularization of the right lobe
plus segment 4 that produce a greater stimulus to hypertrophy of the left lateral segments.
This occurs in less time than other methods above described and allows to reduce the
timeframe between the two steps and minimizes the risk of interprocedural progression of the
underlying disease (incidence of drop outs in the two-stage hepatectomy of 20% for
progression disease).
The morbidity of this two-stage approach was 44% (complications of Clavien grade III and IV)
that mimics the data reported in the literature for extended hepatic resections (20-50%).
The 12%mortality rate was similar to one described by Lang et al for left
trisegmentectomies.
On the basis of the clinical experiences reported the investigators designed a new protocol
of two-stage hepatic resection for the treatment of primary or secondary tumors of the right
lobe. Step1: laparoscopic radio frequency / microwave ablation of the future transection
plane between segment 4 and left lateral lobe and surgical ligation or embolization of the
right portal vein. The ablation has the purpose to devascularize the segment 4 and has the
same significance of the resection of the liver along the falciform ligament described by
the Regensburg group.
Step2: After a period of time of 9 ± 2 days, following a volumetric CT showing an adequate
liver volume gain (ratio FRL / patient body weight> 0.5), the patient undergo the
second-stage surgery: laparoscopic/ laparotomic right trisectionectomy
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01197820 -
Hepatic and Renal Thermography Using Magnetic Resonance Imaging
|
N/A | |
Terminated |
NCT00942383 -
Freehand Ultrasound Elasticity Imaging in Liver Surgery
|
||
Completed |
NCT01782573 -
The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients
|
Phase 4 | |
Active, not recruiting |
NCT03432806 -
A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
|
||
Completed |
NCT01403727 -
Electromagnetic Tracking of Devices During Biopsy Procedures
|
N/A | |
Recruiting |
NCT00691691 -
Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors
|
Phase 2 | |
Terminated |
NCT00955097 -
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
|
Phase 1 | |
Completed |
NCT02162732 -
Molecular-Guided Therapy for Childhood Cancer
|
N/A | |
Recruiting |
NCT05990257 -
CMRA for US-guided-MWA of Liver Tumors
|
N/A | |
Completed |
NCT00828607 -
Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses
|
N/A | |
Completed |
NCT00960609 -
Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study
|
N/A | |
Completed |
NCT05445973 -
Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation
|
N/A | |
Completed |
NCT03171428 -
Hepatectomy With or Without the Thoraco-abdominal Approach
|
N/A | |
Completed |
NCT02509507 -
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
|
Phase 1/Phase 2 | |
Completed |
NCT00877136 -
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
|
||
Terminated |
NCT04315883 -
Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
|
||
Completed |
NCT01031784 -
Radioactive Holmium Microspheres for the Treatment of Liver Metastases
|
Phase 1 | |
Active, not recruiting |
NCT00845689 -
Prevention of Liver Damage During Liver Surgery
|
Phase 1/Phase 2 |